Lead Product(s): INV-101
Therapeutic Area: Genetic Disease Product Name: INV-101
Highest Development Status: Preclinical Product Type: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 08, 2020
Proceeds will be used to develop Inversago’s best-in-class peripherally-acting CB1 inverse agonist candidate INV-101 to clinical proof-of-concept, and advance the research on other selected compounds.
Lead Product(s): ECT-001
Therapeutic Area: Genetic Disease Product Name: ECT-001
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 07, 2020
IRICoR's investment enabled ExCellThera to secure the co-funding required in connection with the grant awarded to it from the California Institute for Regenerative Medicine for a Phase 1 clinical trial using its ECT-001, for the treatment of severe sickle cell disease.